Xiaohang Chen

Ms. Xiaohang Chen


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Cancer Letters
Verified
Journal Article
Closed access
XCXiaohang Chen
Xiaohang Chen
EFEnhui Fu
Enhui Fu
HLHuihuang Lou
Huihuang Lou
XMXionghui Mao
Xionghui Mao
BYBingqing Yan
Bingqing Yan
LWLanlan Wei
Lanlan Wei

11 June 2026 in Discover Oncology
Verified
Journal Article
Open access
YLYanan Liu
Yanan Liu
SWShaojuan Wang
Shaojuan Wang
XXXiaolu Xia
Xiaolu Xia
TZTong Zhang
Tong Zhang
XCXiaohang Chen
Xiaohang Chen
FWFengxiang Wei
Fengxiang Wei
The primary challenges in the clinical treatment of cervical cancer include metastasis, recurrence, proliferation, and drug resistance. DSG2 is a transmembrane desmosomal cadherin, has been implicated in various cancers, but its specific role in cervical cancer remains unclear.Recently, Dihydroartemisinin (DHA) has emerged as a promising antitumor drug. In this study, we aimed to investigate the impact of DSG2 on cervical cancer cells treated with DHA. Cellular assays demonstrated that DHA effectively inhibited the proliferation, migration, and invasion of HeLa cells. Increasing concentrations of DHA prolonged its effects and reduced HeLa cell proliferation. RNA-seq analysis revealed that DHA induced differential gene expression involved in cell migration, protein digestion and absorption, cytokine receptor interaction, the PI3K/AKT signaling pathway, and the Rap1 signaling pathway. DHA downregulated the expression of PI3K and AKT, while upregulating P53, ATM, cleaved caspase-3, and H2AX expression. Overexpression of DSG2 in HeLa cells increased resistance to DHA inhibition, whereas knockdown of DSG2 enhanced the inhibitory effects of DHA. This study highlights that DSG2 modulates the cytotoxicity of DHA, which is potentially associated with the PI3K/AKT signaling pathway, suggesting DSG2 as a candidate biomarker and a potential target for further investigation in cervical cancer.

1 January 2025 in Mediators of Inflammation
Verified
Journal Article
Open access
YLYanan Liu
Yanan Liu
GZGuoqiang Zhao
Guoqiang Zhao
YKYanqing Kong
Yanqing Kong
FZFengyuan Zhou
Fengyuan Zhou
TZTong Zhang
Tong Zhang
FWFengxiang Wei
Fengxiang Wei
CYB5D2 is a novel tumor suppressor gene that exhibits ectopic expression in various tumors. This study explored its significance in cervical cancer screening and prognosis by examining its expression in cervical precancerous lesions and cancer tissues and analyzing follow‐up data. CYB5D2 expression was comprehensively assessed in 112 clinical samples, combined with routine cervical cancer screening methods to evaluate its early detection potential. Postoperative survival data from cervical cancer patients were analyzed using Kaplan–Meier curves to examine the association between CYB5D2 protein expression and clinicopathological characteristics, as well as its prognostic implications. Results revealed a progressive downregulation of CYB5D2 expression with advancing cervical lesions. Immunohistochemical detection of CYB5D2 protein outperformed ThinPrep cytology test (TCT), DNA aneuploidy analysis, and HR‐HPV E6/E7 mRNA testing (mRNA expression of the E6 and E7 genes in high‐risk HPV virus) in diagnosing high‐grade squamous intraepithelial lesions (HSIL+) of the cervix. Combined testing of TCT, HR‐HPV E6/E7 mRNA, and CYB5D2 achieved 100% sensitivity and negative predictive value for HSIL+. In conclusion, low CYB5D2 expression was identified as an independent risk factor for progression‐free survival (PFS) in cervical cancer patients. Incorporating CYB5D2 testing into routine screening protocols for squamous cell lesions, along with TCT and HPV testing, may enhance diagnostic efficiency and provide prognostic value for adverse outcomes.